1.
Ann Oncol
; 23(9): 2470-2471, 2012 Sep.
Article
in English
| MEDLINE
| ID: mdl-22918879
Subject(s)
Alanine Transaminase/blood , Anticholesteremic Agents/pharmacology , Antineoplastic Agents/pharmacology , Neoplasms/blood , Pyrimidines/pharmacology , Simvastatin/pharmacology , Sulfonamides/pharmacology , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/genetics , Anticholesteremic Agents/adverse effects , Anticholesteremic Agents/therapeutic use , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Chemical and Drug Induced Liver Injury/epidemiology , Chemical and Drug Induced Liver Injury/genetics , Clinical Trials as Topic , Drug Interactions , Humans , Hypercholesterolemia/blood , Hypercholesterolemia/drug therapy , Incidence , Indazoles , Neoplasm Proteins/genetics , Neoplasms/drug therapy , Polymorphism, Single Nucleotide , Pyrimidines/adverse effects , Pyrimidines/therapeutic use , Reference Values , Simvastatin/adverse effects , Simvastatin/therapeutic use , Sulfonamides/adverse effects , Sulfonamides/therapeutic use
2.
Endocr Relat Cancer
; 11(2): 255-63, 2004 Jun.
Article
in English
| MEDLINE
| ID: mdl-15163301
ABSTRACT
Copper is a tightly regulated trace element. Disruptions of copper homeostasis are rare and they cause serious disorders such as Wilson's disease and Menkes disease. Copper also plays an important role in promoting physiological and malignant angiogenesis. Formation of new blood vessels by a tumor enables tumor growth, invasion and metastasis. The copper chelator tetrathiomolybdate (TM), which quickly and effectively depletes copper stores, is under investigation as an anti-angiogenic agent. Promising results in vitro, in pre-clinical animal models and in an early (phase I) clinical trial have led to ongoing phase II evaluation of TM in patients with advanced cancers.
